Upon systematic review and meta-analysis of the data from 12 eligible studies, we found that mutant EGFR NSCLC patient harbored BIM wild polymorphism with TKI therapy out-performed the patients with BIM deletion polymorphism in term of RR, DCR and PFS. The gene discussed is BCL2L11; the disease is non-small cell lung carcinoma.